Cancer antigen helper peptide

US9266932B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9266932-B2
Application numberUS-201013265805-A
CountryUS
Kind codeB2
Filing dateApr 22, 2010
Priority dateApr 23, 2009
Publication dateFeb 23, 2016
Grant dateFeb 23, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.

First claim

Opening claim text (preview).

The invention claimed is: 1. A peptide that induces WT1-specific helper T cells by binding to an MHC class II molecule, wherein the peptide is up to 25 amino acids in length, and wherein the peptide comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence depicted in SEQ ID NO:3; and (b) an amino acid sequence in which one amino acid is substituted, deleted or added in the amino acid sequence depicted in (a). 2. The peptide according to claim 1 , wherein the amino acid sequence is the amino acid sequence depicted in SEQ ID NO:3. 3. The peptide according to claim 1 , wherein the MHC class II molecule is selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*0802, DRB1*0803, DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901, DQB1*0301 DQB1*0302 DQB1*0401 DQB1*0501 DQB1*0601 DQB1*0602, and DRB5*0102. 4. The peptide according to claim 1 , wherein the MHC class II molecule is selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*1502, DPB1*0201, DPB1*0202, and DQB1*0601. 5. A pharmaceutical composition for treating or preventing cancer, comprising the peptide according to claim 1 . 6. A method for treating or preventing cancer, which comprises administering an effective amount of the peptide according to claim 1 to a subject having an MHC class II molecule selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*0802, DRB1*0803, DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901, DQB1*0301, DQB1*0302, DQB1*0401, DQB1*0501, DQB1*0601, DQB1*0602, and DRB5*0102. 7. Antigen presenting cells which display the peptide according to claim 1 through an MHC class II molecule selected from the group consisting of DRB1*0101, DRB1*0405 DRB1*0802 DRB1*0803 DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901, DQB1*0301, DQB1*0302, DQB1*0401, DQB1*0501, DQB1*0601, DQB1*0602, and DRB5*0102. 8. A method for inducing antigen presenting cells, which comprises culturing immature antigen presenting cells in the presence of the peptide according to claim 1 , and inducing antigen presenting cells, which display the peptide through an MHC class II molecule selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*0802, DRB1*0803, DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901, DQB1*0301, DQB1*0302, DQB1*0401, DQB1*0501, DQB1*0601, DQB1*0602, and DRB5*0102, from the immature antigen presenting cells. 9. WT1-Specific helper T cells which are induced by the peptide according to claim 1 . 10. A method for inducing WT1-specific helper T cells, which comprises culturing peripheral blood mononuclear cells in the presence of the peptide according to claim 1 , and inducing WT1-specific helper T cells from the peripheral blood mononuclear cells. 11. A kit for inducing WT1-specific helper T cells, comprising, as an essential ingredient, the peptide according to claim 1 . 12. A kit for preventing or treating cancer, comprising, as an essential ingredient, the peptide according to claim 1 .

Assignees

Inventors

Classifications

  • specific for leukemia · CPC title

  • Antineoplastic agents · CPC title

  • for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

  • involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

  • Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9266932B2 cover?
The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
Who is the assignee on this patent?
Sugiyama Haruo, Int Inst Cancer Immunology Inc
What technology area does this patent fall under?
Primary CPC classification C07K14/4702. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).